Analysts Set Climb Bio, Inc. (NASDAQ:CLYM) Price Target at $9.50

Climb Bio, Inc. (NASDAQ:CLYM) has been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $9.50.

A number of brokerages have issued reports on CLYM. William Blair began coverage on Climb Bio in a research report on Thursday, October 16th. They set an “outperform” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research report on Wednesday, January 21st. Wall Street Zen cut shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. BTIG Research restated a “buy” rating and set a $8.00 price target on shares of Climb Bio in a research report on Thursday, October 16th. Finally, HC Wainwright increased their price objective on shares of Climb Bio from $9.00 to $11.00 and gave the company a “buy” rating in a report on Thursday, December 18th.

Climb Bio Trading Down 5.2%

Shares of NASDAQ CLYM opened at $5.27 on Friday. Climb Bio has a 12-month low of $1.05 and a 12-month high of $5.86. The company has a market cap of $359.31 million, a PE ratio of -6.93 and a beta of -0.15. The stock has a 50 day simple moving average of $4.29 and a 200-day simple moving average of $2.78.

Insider Transactions at Climb Bio

In other news, Director Ra Capital Management, L.P. purchased 213,099 shares of the stock in a transaction dated Thursday, December 11th. The shares were bought at an average cost of $2.18 per share, for a total transaction of $464,555.82. Following the transaction, the director owned 3,294,856 shares in the company, valued at $7,182,786.08. This trade represents a 6.91% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last three months, insiders acquired 321,672 shares of company stock worth $779,626. Company insiders own 0.80% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CLYM. Peapod Lane Capital LLC raised its position in Climb Bio by 0.7% in the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock worth $2,264,000 after acquiring an additional 4,126 shares in the last quarter. ADAR1 Capital Management LLC grew its stake in shares of Climb Bio by 11.9% in the 3rd quarter. ADAR1 Capital Management LLC now owns 133,530 shares of the company’s stock worth $268,000 after purchasing an additional 14,210 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Climb Bio in the 3rd quarter worth approximately $29,000. AQR Capital Management LLC acquired a new stake in Climb Bio during the first quarter valued at approximately $27,000. Finally, UBS Group AG boosted its holdings in Climb Bio by 6.0% during the third quarter. UBS Group AG now owns 405,404 shares of the company’s stock worth $815,000 after buying an additional 22,922 shares in the last quarter. Institutional investors own 69.76% of the company’s stock.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.